Showing 3341-3350 of 4063 results for "".
- Zeiss Acquires All Shares of Tooz, Maker of Augmented Reality Opticshttps://modernod.com/news/zeiss-acquires-tooz-maker-of-augmented-reality-and-virtual-reality-glasses/2481447/Zeiss announced it has acquired the shares of the joint venture tooz technologies, which was founded together with Deutsche Telekom in 2018 and is developer of high-tech optics in the area of augmented reality. Until now, Zeiss and Deutsche Telekom held 50% of the shares in the sta
- Akorn Files for Chapter 7 Bankruptcy; to Close All US Siteshttps://modernod.com/news/akorn-pharma-to-close-all-us-sites/2481445/Akorn Pharmaceuticals, a maker of generic and branded drugs, announced it is ceasing operations. The company, which offered more than 20 ophthalmic products, has filed for chapter 7 bankruptcy and is shutting down US operations. The news was first
- FDA Accepts for Priority Review NDA for Primary Vitreoretinal Lymphoma Treatment Candidatehttps://modernod.com/news/fda-accepts-for-priority-review-adx-2191-new-drug-application-for-the-treatment-of-primary-vitreoretinal-lymphoma/2481442/Aldeyra Therapeutics announced that the FDA accepted for Priority Review the new drug application (NDA) for ADX-2191 (methotrexate injection, USP), an investigational drug candidate for the treatment of primary vitreoretinal lymphoma. The FDA assigned a Prescription Drug User Fee A
- Notal Vision: Clinical Trials Demonstrate Value of Home OCThttps://modernod.com/news/notal-vision-clinical-trials-demonstrate-value-of-home-oct/2481429/Notal Vision reported that the latest data on its investigational home-based optical coherence tomography (OCT) and how the service can be used to manage wet age-related macular degeneration (AMD) were recently presented at the Angiogenesis, Exudation, and Degeneration and Macula Society 202
- FDA Accepts Orasis Pharmaceuticals' NDA for CSF-1 for the Treatment of Presbyopiahttps://modernod.com/news/fda-accepts-orasis-pharmaceuticals-nda-for-csf-1-for-the-treatment-of-presbyopia/2481424/Orasis Pharmaceuticals announced that the FDA has accepted for review its new drug application (NDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 22, 2023. "We
- Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-positive-data-on-cls-ax-oasis-clinical-trial-and-use-of-scs-microinjector/2481423/Clearside Biomedical announced data from presentations delivered at the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting. “The promising durability data from our OASIS clinical trial continues to garner si
- Vision Expo East Announces Keynote Speakerhttps://modernod.com/news/vision-expo-east-announces-keynote-speaker/2481419/Vision Expo East announced that Jason Romero, a legally blind ultra-runner, will be the keynote speaker at the annual conference in New York City from March 16-19, 2023 (Education opens March 16; Exhibits open March 17). “After losing his vision to a dege
- Brent Saunders Returns to Bausch + Lomb as CEO and Chair of the Board of Directorshttps://modernod.com/news/brent-saunders-returns-to-bausch-lomb-to-serve-as-ceo-and-chair-of-the-board-of-directors/2481411/After nearly a decade, pharma executive Brent Saunders is returning to Bausch + Lomb where he will serve as CEO and Chair of the Board of Directors, effective March 6, 2023. Mr. Saunders served as Bausch + Lomb's CEO from 2010 to 2013 before its sale to Valeant Pharmaceuti
- FDA Accepts Ocuphire's NDA for Nyxol Eye Drops for Reversal of Mydriasishttps://modernod.com/news/fda-accepts-ocuphires-new-drug-application-for-nyxol-eye-drops-for-reversal-of-mydriasis/2481404/Ocuphire Pharma announced that the FDA has accepted the new drug application (NDA) for Nyxol (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis (RM). The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of September 28, 2023.
- Allegro Ophthalmics Provides Updates on Dry AMD Pipeline Candidateshttps://modernod.com/news/allegro-ophthalmics-provides-updates-on-dry-amd-pipeline-candidates/2481403/Allegro Ophthalmics announced the presentation of data supporting dry AMD pipeline candidates, including risuteganib (Luminate), at the Bascom Palmer Eye Institute's 20th annual